Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy

This clinical study aims to determine if skipping breast and axillary surgery could provide similar control of local and distant disease, with fewer complications and better quality of life, for triple-negative breast cancer patients in complete response after neoadjuvant chemo-immunotherapy. Patients will be randomised into 2 groups : * Control arm will receive the standard treatment, including surgery * Experimental arm will receive the standard treatment, except surgery

NCT Number	NCT07357948
Lead Sponsor	Institut Curie
Conditions	Triple Negative Breast Cancer, Non-Metastatic
Enrollment	150 participants
Start Date	2026-08-01
Primary Completion	2031-07-31 (estimated)
Study Completion	2033-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-03